Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 637-643

  Efstathiou, Eleni ^a,b   Titus, Mark ^c   Tsavachidou, Dimitra ^a   Tzelepi, Vassiliki ^a   Wen, Sijin ^a   Hoang, Anh ^a   Molina, Arturo ^d   Chieffo, Nicole ^d   Smith, Lisa A ^a   Karlou, Maria ^a   Troncoso, Patricia ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Ortho Biotech Oncology Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; CYTOCHROME P450 17; PREDNISONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE METASTASIS; BONE SCINTISCANNING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG SAFETY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENOLS; BONE MARROW; BONE NEOPLASMS; CASTRATION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REMISSION INDUCTION; TESTOSTERONE; VASCULAR DISEASES; YOUNG ADULT;

EID: 84863393126     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.7675     Document Type: Article

References (21)

1. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179, 2002 (Pubitemid 34546107)
2. Geller J: Prolonging survival in metastatic prostate cancer: The case for adrenal androgens - Overview and summary of therapeutic controversies in prostatic cancer. J Clin Endocrinol Metab 80:1074-1078, 1995
3. Mohler JL, Gregory CW, Ford OH, et al: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448, 2004 (Pubitemid 38173980)
4. Titus MA, Schell MJ, Lih FB, et al: Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657, 2005 (Pubitemid 41557182)
5. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
6. Attard G, Reid AH, A'Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748, 2009
7. Danila DC, Morris MJ, de Bono JS, et al: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496-1501, 2010
8. Reid AH, Attard G, Danila DC, et al: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489-1495, 2010
9. Ryan CJ, Smith MR, Fong L, et al: Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481-1488, 2010
10. Attard G, Reid AH, Olmos D, et al: Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937-4940, 2009
11. Scher HI, Beer TM, Higano CS, et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 375: 1437-1446, 2010
12. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
13. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
14. Efstathiou E, Troncoso P, Wen S, et al: Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13:1224-1231, 2007 (Pubitemid 46424064)
15. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041, 2007 (Pubitemid 46910214)
16. Stanbrough M, Bubley GJ, Ross K, et al: Increased expression of genes converting adrenal androgens to testosterone in androgenin-dependent prostate cancer. Cancer Res 66: 2815-2825, 2006
17. Efstathiou E, Logothetis CJ: A new therapy paradigm founded on clinical observation. Clin Cancer Res 16:1100-1107, 2010
18. Taplin ME, Bubley GJ, Shuster TD, et al: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995
19. Lou YR, Nazarova N, Talonpoika R, et al: 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells. Prostate 63:222-230, 2005 (Pubitemid 40571056)
20. Thomas LN, Douglas RC, Lazier CB, et al: Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53:244-252, 2008 (Pubitemid 350296595)
21. Penning TM: New frontiers in biosynthesis and metabolism. Curr Opin Endocrinol Diabetes Obes 17:233-239, 2010